Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.

Literature DB >> 27357340

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.

Maud Deruaz¹, Brian Moldt², Khoa M Le², Karen A Power³, Vladimir D Vrbanac⁴, Serah Tanno⁴, Musie S Ghebremichael³, Todd M Allen³, Andrew M Tager⁴, Dennis R Burton⁵, Andrew D Luster¹.

Abstract

Humanized mice reconstituted with a human immune system can be mucosally infected with human immunodeficiency virus (HIV), opening up the possibility of studying HIV transmission in a small-animal model. Here we report that passive immunization with the broadly neutralizing antibody b12 protected humanized mice against repetitive intravaginal infection in a dose-dependent manner. In addition, treatment with the antibody PGT126, which is more potent in vitro, was more efficacious in vivo and provided sterilizing protection. Our results demonstrate that humanized mice can be used as a small-animal model to study the efficacy and mechanism of broadly neutralizing antibody protection against HIV acquisition.

Entities: Chemical Disease Species

Keywords: HIV transmission; humanized mice; mucosal infection; neutralizing antibodies

Mesh：

Substances：

Year: 2016 PMID： 27357340 PMCID： PMC4957443 DOI： 10.1093/infdis/jiw203

Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226

15 in total

Review 1. The chimpanzee and other non-human-primate models in HIV-1 vaccine research.

Authors: B M Nath; K E Schumann; J D Boyer
Journal: Trends Microbiol Date: 2000-09 Impact factor: 17.079

2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Authors: Marina Caskey; Florian Klein; Julio C C Lorenzi; Michael S Seaman; Anthony P West; Noreen Buckley; Gisela Kremer; Lilian Nogueira; Malte Braunschweig; Johannes F Scheid; Joshua A Horwitz; Irina Shimeliovich; Sivan Ben-Avraham; Maggi Witmer-Pack; Martin Platten; Clara Lehmann; Leah A Burke; Thomas Hawthorne; Robert J Gorelick; Bruce D Walker; Tibor Keler; Roy M Gulick; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig
Journal: Nature Date: 2015-04-08 Impact factor: 49.962

3. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.

Authors: Eun Mi Hur; Sonal N Patel; Saki Shimizu; Dinesh S Rao; Priyanthi N P Gnanapragasam; Dong Sung An; Lili Yang; David Baltimore
Journal: Blood Date: 2012-10-11 Impact factor: 22.113

4. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

Authors: Milena Veselinovic; C Preston Neff; Leila R Mulder; Ramesh Akkina
Journal: Virology Date: 2012-07-24 Impact factor: 3.616

5. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors: Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal: Cell Date: 2014-09-11 Impact factor: 41.582

6. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors: Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal: Proc Natl Acad Sci U S A Date: 2012-10-25 Impact factor: 11.205

7. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Authors: Henning Gruell; Stylianos Bournazos; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig; John Pietzsch
Journal: J Virol Date: 2013-05-29 Impact factor: 5.103

8. Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors: Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal: Nature Date: 2011-09-22 Impact factor: 49.962

9. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission.

Authors: Alejandro B Balazs; Yong Ouyang; Christin M Hong; Joyce Chen; Steven M Nguyen; Dinesh S Rao; Dong Sung An; David Baltimore
Journal: Nat Med Date: 2014-02-09 Impact factor: 53.440

10. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Authors: Ariel Halper-Stromberg; Joshua A Horwitz; Florian Klein; Henning Gruell; Johannes F Scheid; Stylianos Bournazos; Hugo Mouquet; Linda A Spatz; Ron Diskin; Alexander Abadir; Trinity Zang; Marcus Dorner; Eva Billerbeck; Rachael N Labitt; Christian Gaebler; Paola Marcovecchio; Reha-Baris Incesu; Thomas R Eisenreich; Paul D Bieniasz; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal: Nature Date: 2012-10-24 Impact factor: 49.962

19 in total

1. Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice.

Authors: Anne-Sophie Kuhlmann; Kevin G Haworth; Isaac M Barber-Axthelm; Christina Ironside; Morgan A Giese; Christopher W Peterson; Hans-Peter Kiem
Journal: Mol Ther Date: 2018-09-27 Impact factor: 11.454

Review 2. Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors: Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal: Immunol Rev Date: 2017-01 Impact factor: 12.988

3. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.

Authors: Salar N Khan; Devin Sok; Karen Tran; Arlette Movsesyan; Viktoriya Dubrovskaya; Dennis R Burton; Richard T Wyatt
Journal: J Virol Date: 2018-08-29 Impact factor: 5.103

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.

Review 1. The chimpanzee and other non-human-primate models in HIV-1 vaccine research.

2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

3. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.

4. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

5. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

6. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

7. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

8. Broad neutralization coverage of HIV by multiple highly potent antibodies.

9. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission.

10. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1. Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice.

Review 2. Use of broadly neutralizing antibodies for HIV-1 prevention.

3. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.

Review 4. Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Review 5. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Review 6. Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

7. Tracking Human Immunodeficiency Virus-1 Infection in the Humanized DRAG Mouse Model.

8. Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.

Review 9. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.

Review 10. Antibody-mediated prevention and treatment of HIV-1 infection.